Working… Menu

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04260009
Recruitment Status : Withdrawn (Business reason unrelated to product safety)
First Posted : February 7, 2020
Last Update Posted : March 5, 2020
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : September 1, 2025